SMARCC1: A Potential Drug Target for Alzheimer's and Heart Failure

Target Name: SMARCC1

NCBI ID: G6599

SMARCC1

SMARCC1: A Potential Drug Target for Alzheimer's and Heart Failure

SMARCC1 (CRACC1) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and liver. It is a member of the CRACC family, which includes proteins that are involved in cell-signaling pathways.

SMARCC1 was first identified as a potential drug target by researchers at the University of California, San Diego. They found that SMARCC1 was expressed in the brains of individuals with Alzheimer's disease, and that levels of the protein were significantly higher in individuals with the disease than in those without it.

The researchers also found that SMARCC1 was expressed in the hearts of individuals with heart failure, and that levels of the protein were significantly higher in individuals with the condition than in those without it.

These findings suggest that SMARCC1 may be a useful drug target for the treatment of Alzheimer's disease and heart failure.

SMARCC1 is also a potential biomarker for these conditions. The researchers found that levels of SMARCC1 were significantly higher in the brains and hearts of individuals with Alzheimer's disease and heart failure than in those without the disease. This suggests that SMARCC1 may be a useful biomarker for the diagnosis and treatment of these conditions.

In addition to its potential drug and biomarker applications, SMARCC1 is also of interest to researchers because of its role in cell-signaling pathways. The CRACC family of proteins is known for its ability to regulate cell-signaling pathways, and SMARCC1 is thought to play a similar role.

Overall, SMARCC1 is a protein that is of interest to researchers because of its potential as a drug target and biomarker for the treatment of Alzheimer's disease and heart failure. Further research is needed to fully understand its role in these conditions and to develop effective treatments.

Protein Name: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin Subfamily C Member 1

Functions: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. May stimulate the ATPase activity of the catalytic subunit of the complex (PubMed:10078207, PubMed:29374058). Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity)

The "SMARCC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets